Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer. - Wikidata - awgldk - TriplyDB

Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer.

Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer.

http://www.wikidata.org/entity/Q33499198

about

Clinical indications for thrombopoietin and thrombopoietin-receptor agonists Cytokines and hematopoietic stem cell mobilization Selective enhancement of thrombopoietic activity of PEGylated interleukin 6 by a simple procedure using a reversible amino-protective reagent.Enhanced retention of in vitro functional activity of platelets from recombinant human thrombopoietin-treated patients following long-term cryopreservation with a platelet-preserving solution (ThromboSol) and 2% DMSO.Platelet growth factors: potential impact on transfusion medicine.Endogenous thrombopoietin serum levels during multicycle chemotherapy.Immunogenicity of thrombopoietin mimetic peptide GW395058 in BALB/c mice and New Zealand white rabbits: evaluation of the potential for thrombopoietin neutralizing antibody production in man.Thrombopoietin.Pharmacokinetics, pharmacodynamics, and safety of administering pegylated recombinant megakaryocyte growth and development factor to newborn rhesus monkeys.Phase 1 study of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in breast cancer patients after autologous peripheral blood progenitor cell (PBPC) transplantation.Dose-response relationship of megakaryocyte progenitors from the bone marrow of thrombocytopenic and non-thrombocytopenic neonates to recombinant thrombopoietin.The pharmacokinetics and pharmacodynamics of GW395058, a peptide agonist of the thrombopoietin receptor, in the dog, a large-animal model of chemotherapy-induced thrombocytopenia.Effects of Mpl ligands on platelet production and function in nonhuman primates.Endogenous TPO (eTPO) levels in health and disease: possible clues for therapeutic intervention.Opportunities for the use of thrombopoietic growth factors.Recombinant human thrombopoietin (rhTPO) after autologous bone marrow transplantation: a phase I pharmacokinetic and pharmacodynamic study.Failing to live up to the fanfare? A personal perspective on obstacles to the clinical development of thrombopoietic agents.Serum levels of endogenous thrombopoietin and granulocyte-colony stimulating factor in patients with acute or lymphoma type adult T-cell leukemia during multicycle chemotherapy.Thrombopoietin as a drug: biologic expectations, clinical realities, and future directions.New TPO treatment schedules of increased safety and efficacy: pre-clinical validation of a thrombopoiesis simulation model.Endogenous thrombopoietin levels during the clinical management of acute myeloid leukaemia.Review article: thrombocytopenia in chronic liver disease and pharmacologic treatment options.A rationally designed agonist antibody fragment that functionally mimics thrombopoietin The incidence and impact of thrombocytopenia in myelodysplastic syndromes.Review article: pharmacological approaches for the treatment of thrombocytopenia in patients with chronic liver disease and hepatitis C infection.New drugs for familiar therapeutic targets: thrombopoietin receptor agonists and immune thrombocytopenic purpura.AKR-501 (YM477) a novel orally-active thrombopoietin receptor agonist.New advances in the treatment of adult chronic immune thrombocytopenic purpura: role of thrombopoietin receptor-stimulating agents.Development of romiplostim for the treatment of patients with chronic immune thrombocytopenia: from bench to bedside.Thrombocytopenia in patients with myelodysplastic syndromes.Toxicities of the thrombopoietic growth factors Eltrombopag--a novel approach for the treatment of chronic immune thrombocytopenic purpura: review and safety considerations.The biology of thrombopoietin and thrombopoietin receptor agonists.Diagnosis and management of autoimmune cytopenias in childhood.Thrombopoietin from beginning to end.Pharmacodynamic model for chemoradiotherapy-induced thrombocytopenia in mice.Eltrombopag for treatment of thrombocytopenia-associated disorders.Development of Romiplostim for Treatment of Primary Immune Thrombocytopenia From a Pharmacokinetic and Pharmacodynamic Perspective.Thrombocytopenia-Platelet Support or Growth Factors?Thrombocytopenia in Patients with Chronic Hepatitis C Virus Infection

P2860

Q24601161-0971AAF9-67D7-45B2-9ADA-032A66A309DD Q28255913-E31AB507-CBCB-4FBF-8158-E3664A1722C5 Q31893425-BDDE734D-A0B6-4B25-9979-FF245162A80B Q33328017-B9C2F0DB-37D4-4860-AD98-820AB6A22211 Q33328500-B41FC7D8-2145-4BFC-9B51-0A881A65E873 Q33329048-527B3D42-273C-41F2-9F1E-18FA47A926FB Q33329667-08AC7E76-179A-4427-9A45-333A4502406E Q33330090-9943D6F7-3D18-486D-BCD5-99712865B225 Q33331487-BCBCE037-0E41-41D1-A6AD-688F0142A398 Q33333334-07E761B6-5C30-4C12-AA9E-63D90DFE5276 Q33333937-06C2C5B6-45E4-4AA7-A94B-0AB9CDE542DA Q33334322-A2E34F61-C77F-4704-81F3-0ABB6B3032D7 Q33334358-02151DE8-B406-457E-A772-63AB968E07C7 Q33334368-4CA23394-0A5D-4198-8EA1-F333B39B1E2D Q33334386-15FCB491-FFCF-4FEC-A370-D24296150469 Q33336625-868921A5-1E23-4342-B11F-895BB4CD5274 Q33340623-9650F2CA-6191-42D1-92BD-D069911CC18E Q33342331-27030999-091E-4E9B-9AF0-4820F425B5AF Q33344528-6496CAD3-1C4E-48C2-8D80-FA03A299552A Q33357606-CAF61EC1-E526-490F-B1A8-F3CAD004A77C Q33365351-E17FF77D-94B6-426D-A7A7-E65F3A425078 Q33370831-935ABC1E-30AE-46BD-8CE6-1F700CA97769 Q33372657-D304E127-CBE9-440D-8E06-F1D94F635703 Q33374593-EE2EF553-6C11-4E41-B46A-7EC2BC380452 Q33377131-0593E304-2F74-4A5B-9B4F-B57A01C2A796 Q33378370-FBBA80FB-C5EF-4972-B7CE-3F87627B8A11 Q33383059-AEB3DC0F-0F67-425B-B6AC-BEB15251721F Q33387735-203FFB60-684C-43AC-9968-C3E8C5FA2290 Q33388773-88B09A16-9AAD-4D69-878C-7A9BCA64088B Q33390639-3B21B3C4-B678-4E2C-88F0-09CBD689301E Q33390645-9E3898DF-725E-4905-A898-9281069045AE Q33391229-810FBC7C-A2D4-40A1-B78E-2EF1472FE75F Q33408850-8DA01350-2D7E-4704-BAD9-AC9FE72E89FD Q33411497-E579D5F9-B820-4CEA-9A25-75516E065668 Q33413170-FC3DA5F8-CF48-4061-8EA9-D59CC8318006 Q33425648-0E79C494-C391-4A7A-8229-31ED1515FD34 Q33425805-C3BA90F9-E453-429F-95B4-A1BA0D88AB40 Q33431320-1F459B29-7E12-45EB-966F-DC95C0D15429 Q33433930-E17C4602-CC2D-44AD-95EB-E0A1C9CB3017 Q33440130-EC28AF11-EAB0-4651-94CD-B355A76AE54A

P2860

Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer.

http://www.wikidata.org/entity/Q33499198

description

1997 nî lūn-bûn

@nan

1997 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

1997 թվականի մայիսին հրատարակված գիտական հոդված

@hy

1997年の論文

@ja

1997年論文

@yue

1997年論文

@zh-hant

1997年論文

@zh-hk

1997年論文

@zh-mo

1997年論文

@zh-tw

1997年论文

@wuu

name

Stimulation of megakaryocyte a ...... ietin in patients with cancer.

@ast

Stimulation of megakaryocyte a ...... ietin in patients with cancer.

@en

type

label

Stimulation of megakaryocyte a ...... ietin in patients with cancer.

@ast

Stimulation of megakaryocyte a ...... ietin in patients with cancer.

@en

prefLabel

Stimulation of megakaryocyte a ...... ietin in patients with cancer.

@ast

Stimulation of megakaryocyte a ...... ietin in patients with cancer.

@en

P1433

Q33499198-EE4F4F96-D9E1-4978-B0AF-FD73F3ABFEC8

P1476

Q33499198-A64C2626-F2F7-4D87-A407-1AE54C5D8043

P2093

Q33499198-0CE4719D-D9D0-40DB-8C8E-7EEAB7B3FE7F

Q33499198-27C426E7-AF32-41BE-9E06-2D5C823596D5

Q33499198-2A434A78-8DFE-49C6-A427-3D7D09AE68E9

Q33499198-316AED4A-E2EE-48A9-AE0F-A95533FB21DC

Q33499198-477170E7-A494-41D7-88FA-0BEBB3FC1FF1

Q33499198-47894A96-5B4E-4301-B796-3CD10037CD5F

Q33499198-4AA8153D-416B-4B9A-B22A-31E6D3DCECED

Q33499198-50C61FA3-47D7-4924-A237-E509648D133E

Q33499198-5FEA2F78-8109-4DFE-848A-19F7E5895838

Q33499198-70E0202B-93DB-4C9D-8039-8E7743003860

P304

Q33499198-90AE6E68-1748-4A2A-B246-76D00E71AA9A

P31

Q33499198-D3B54063-F3F4-4E65-A5B9-B94255A3964A

P356

Q33499198-A541F015-977E-4138-B687-EF404F0326EB

P407

Q33499198-0E486E90-C2E9-44FE-ACE8-AEBB5C1BE6A6

P433

Q33499198-237DE38B-5248-4A5C-A0EE-FB5533197FF3

P478

Q33499198-50243CCE-A8A1-419F-AF50-A5707EF16685

P577

Q33499198-D561D67E-CA76-4562-988A-C4E8DE51F130

P698

Q33499198-52C55E04-A044-46EA-B500-D61392B49DB7

P356

0003-4819-126-9-199705010-00001

P1433

Annals of Internal Medicine

P1476

Stimulation of megakaryocyte a ...... ietin in patients with cancer.

@en

P2093

Benjamin RS

http://www.w3.org/2001/XMLSchema#string

Broxmeyer HE

http://www.w3.org/2001/XMLSchema#string

Bueso-Ramos C

http://www.w3.org/2001/XMLSchema#string

Cohen RL

http://www.w3.org/2001/XMLSchema#string

Hellmann SD

http://www.w3.org/2001/XMLSchema#string

Hittelman WN

http://www.w3.org/2001/XMLSchema#string

Hoots WK

http://www.w3.org/2001/XMLSchema#string

Johnston DA

http://www.w3.org/2001/XMLSchema#string

Johnston T

http://www.w3.org/2001/XMLSchema#string

Murray LJ

http://www.w3.org/2001/XMLSchema#string

P304

673-681

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.7326/0003-4819-126-9-199705010-00001

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

126

http://www.w3.org/2001/XMLSchema#string

P577

1997-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

9139552

http://www.w3.org/2001/XMLSchema#string